# Study to Assess the Safety and Effectiveness of Beltavac® Polymerized With Alternaria Alternata

> **NCT03604718** · — · COMPLETED · sponsor: **Probelte Pharma S.L.U.** · enrollment: 65 (actual)

## Conditions studied

- Rhinoconjunctivitis With or Without Allergic Asthma

## Interventions

- **BIOLOGICAL:** Beltavac® Polymerized with Alternaria alternata

## Key facts

- **NCT ID:** NCT03604718
- **Lead sponsor:** Probelte Pharma S.L.U.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-07
- **Primary completion:** 2023-01-20
- **Final completion:** 2023-01-20
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2023-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03604718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03604718, "Study to Assess the Safety and Effectiveness of Beltavac® Polymerized With Alternaria Alternata". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03604718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*